Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Abivax S.A.
Abivax S.A.
Pfizer
Janssen Scientific Affairs, LLC
Oppilan Pharma Ltd
Takeda
Hoffmann-La Roche
Hoffmann-La Roche
Hoffmann-La Roche
National Cancer Institute (NCI)
Hoffmann-La Roche
Hoffmann-La Roche
Takeda
Oxford University Hospitals NHS Trust
Hutchmed
CosmoTech
W.L.Gore & Associates
AbbVie
Integra LifeSciences Corporation
King Fahad Medical City
Mayo Clinic